Noninvasive Assessment of Hepatic Steatosis in Living Liver Donors
Diagnostics · 04.03.2026 · 16 (5) · 772
DOI: 10.3390/diagnostics16050772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 04.03.2026. Verfasst von Iman Al-Saleh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Health Program, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Faisal Specialist Hospital and Research Center.
Abstract (Originalsprache)
Background & Aims: The accurate, noninvasive assessment of hepatic steatosis is essential in living liver donor evaluation, where disease prevalence is low, and donor safety is paramount. This study evaluated commonly used noninvasive diagnostic tools for detecting hepatic steatosis in a real-world donor screening setting.
Methods
We analyzed 108 living liver donor candidates (18–53 years) with complete MRI, CT, transient elastography (FibroScan®), and biochemical data obtained during routine donor evaluation. Hepatic steatosis was defined as an MRI-proton density fat fraction (PDFF) ≥5%, which served as the noninvasive reference standard. Diagnostic performance metrics, receiver operating characteristic (ROC) analyses, and correlations with serum fibrosis indices (FIB-4 and APRI) were assessed.
Results
MRI-PDFF identified hepatic steatosis in 21 donors (19.4%). Controlled attenuation parameter (CAP), measured by transient elastography, demonstrated high sensitivity (90.5%) and negative predictive value (97.1%), supporting its role as a rule-out screening tool. CT showed excellent specificity (97.7%) but lower sensitivity (61.9%), consistent with a confirmatory role when MRI is unavailable. Serum fibrosis indices were generally low and did not correlate strongly with imaging-based steatosis.
Conclusions
In the low-prevalence setting of living liver donor evaluation, CAP-based transient elastography provides effective noninvasive screening for hepatic steatosis, while MRI-PDFF serves as a confirmatory reference when indicated. These findings support a stepwise, clinically practical diagnostic approach that prioritizes donor safety and workflow efficiency.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Environmental Health Program, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
- Gastroenterology Section, Department of Medicine, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
- Transplant Endoscopy Unit, Liver and Small Bowel Health Centre, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
- School of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
ORCID-Profile: Iman Al-Saleh
Förderung
- King Faisal Specialist Hospital and Research Center
Zitieren
APA
Al-Saleh, I., Alashgar, H., Albenmousa, A., Alsaeed, R., & Jamal, M. (2026). Noninvasive Assessment of Hepatic Steatosis in Living Liver Donors. Diagnostics, 16(5), 772. https://doi.org/10.3390/diagnostics16050772
Vancouver
Al-Saleh I, Alashgar H, Albenmousa A, Alsaeed R, Jamal M. Noninvasive Assessment of Hepatic Steatosis in Living Liver Donors. Diagnostics. 2026;16(5):772. doi:10.3390/diagnostics16050772
BibTeX
@article{AlSaleh2026,
author = {Al-Saleh, Iman and Alashgar, Hamad and Albenmousa, Ali and Alsaeed, Ruba and Jamal, Madiha},
title = {Noninvasive Assessment of Hepatic Steatosis in Living Liver Donors},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {5},
pages = {772},
doi = {10.3390/diagnostics16050772}
}
EUVIMED